Search
for
Sort by
Research 181–210 of 788
- Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients
- Oclacitinib Treatment and Surgical Management in a Case of Periocular Eosinophilic Furunculosis and Vasculitis with Secondary Eyelid Fusion in a Diabetic Cat
- Economic Burden of Alopecia Areata in the Kingdom of Saudi Arabia from a Societal Perspective: A Cost-of-Illness Analysis
- JAK inhibition decreases the autoimmune burden in Down syndrome
- Genes and Immune Response in Alopecia Areata: Review of the Alopecia Areata Research Summit First Day Proceedings
- Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature
- Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata
- Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
- 277 An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata
- 3-Deoxysappanchalcone Promotes Proliferation of Human Hair Follicle Dermal Papilla Cells and Hair Growth in C57BL/6 Mice by Modulating WNT/β-Catenin and STAT Signaling
- Case Report: Repigmentation and complete hair regrowth in an 11-year-old preadolescent with alopecia totalis treated with a JAK inhibitor
- Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial
- Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
- A novel therapeutic paradigm for patients with extensive alopecia areata
- Current and future pharmacotherapy for alopecia areata
- At the crossroads of 2 alopecias: Androgenetic alopecia pattern of hair regrowth in patients with alopecia areata treated with oral Janus kinase inhibitors
- A Bibliometric Analysis of Alopecia Areata Literature over the Past 50 Years.
- Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers
- Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis
- New small molecules in dermatology: for the autoimmunity, inflammation and beyond
- Clinical Perspectives on Alopecia: From Hair Follicle Biology to Advanced Therapies
- Real-World Experience of Tofacitinib and Baricitinib Use in Alopecia Areata in Greek Population: A Retrospective Analysis With Focus on Safety
- Improvement of Psoriasis, Psoriatic Arthritis, and Alopecia Universalis during Treatment with Tofacitinib: A Case Report
- Alopecia areata: from immunopathogenesis to emerging therapeutic approaches
- New drugs under investigation for the treatment of alopecias
- Janus Kinase inhibitors in dermatology: a review
- Ritlecitinib: First Approval
- The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm
- Efficacy of topical tofacitinib in promoting hair growth in non-scarring alopecia: possible mechanism via VEGF induction
- 219 STAT5 activation in the dermal papilla is important for hair follicle growth phase induction, hair follicle regeneration and wound healing